By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
| Currency | US Dollars |
| Share Price | $ 165.38 |
| Change Today | $ 0.96 |
| % Change | 0.58 % |
| 52 Week High | $165.61 |
| 52 Week Low | $160.36 |
| Volume | 1,879,905 |
| Shares Issued | 145.80m |
| Market Cap | $24,112m |
| Beta | 0.01 |
| RiskGrade | 259 |
| Strong Buy | 8 |
| Buy | 6 |
| Neutral | 19 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 34 |

| Time | Volume / Share Price |
| 15:59 | 100 @ $165.30 |
| 15:59 | 102 @ $165.29 |
| 15:59 | 100 @ $165.39 |
| 15:59 | 100 @ $165.37 |
| 15:59 | 150 @ $165.39 |
You are here: research